Improved myocardial perfusion in stable angina pectoris by oral lumbrokinase: A pilot study

Journal of Alternative and Complementary Medicine

Volumn 15, Issue 5, 2009, Pages 539-544

  Kasim, Manoefris ^a   Kiat, Andrew Alexander ^b   Rohman, Mohammad Saifur ^a   Hanifah, Yasmina ^a   Kiat, Hosen ^c,d  

^a UNIVERSITY OF INDONESIA   (Indonesia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d Cardiac Health Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; LUMBROKINASE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITRIC ACID DERIVATIVE; THROMBOLES; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY CARE UNIT; DRUG EFFICACY; HEART MUSCLE PERFUSION; HUMAN; IMAGE ANALYSIS; INDONESIA; LOW DRUG DOSE; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STABLE ANGINA PECTORIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; ANGINA PECTORIS; ANIMALS; COHORT STUDIES; CORONARY ARTERY DISEASE; ENDOPEPTIDASES; FIBRINOLYTIC AGENTS; HUMANS; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; OLIGOCHAETA; PILOT PROJECTS; SECONDARY PREVENTION; TECHNETIUM TC 99M SESTAMIBI;

EID: 67149144584     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2008.0506     Document Type: Article

References (28)

1. Fox K, Garcia MAA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: Executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-1381.
2. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997;18:394-413.
3. Friedewald VE, King SB, Pepine CJ, et al. The editor's roundtable: Chronic stable angina pectoris. Am J Cardiol 2007;100:1635-1643.
4. O'Rourke RA, O'Gara PT, Leslee JS, Douglas JS. Diagnosis and management of patients with chronic ischemic heart disease. In: Fuster V, et al. Hurst, The Heart, 12th ed. New York: The McGraw Hill Companies, 2008:1491-1493.
5. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: A meta-analysis. Am J Med 2008;121:43-49.
6. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):265S-286S.
7. Mihara H, Sumi H, Yoneta T, et al. A novel fibrinolytic enzyme extracted from the earthworm, Lumbricus rubellus. Jpn J Physiol 1991;41:461-472.
8. Jin L, Jin H, Zhang G, Xu G. Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase. Clin Hemorheo Microcirc 2000;23:213-218.
9. Pang S. A clinical study of therapeutic effectiveness in treating ischemic cerebrovascular disease with lumbrokinase. Chin J Neurol Psychiatry 1993;26:229-231.
10. Cho IH, Choi ES, Lim HG, Lee HH. Purification and characterization of six fibrinolytic serine-proteases from earthworm Lumbricus rubellus. J Biochem Mol Biol 2004;37:199-205.
11. Amanullah A, Kiat H, Friedman JD, Berman DS. Adenosine technetium-99m sestamibi myocardial perfusion SPECT in women: Diagnostic efficacy in detection of coronary artery disease. J Am Coll Cardiol 1996;27:803-809.
12. Berman DS, Kiat H, Friedman JD, et al. Separate acquisition rest thallium201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: A clinical validation study. J Am Coll Cardiol 1993;22:1455-1464.
13. Hachamovitch R, Berman DS, Kiat H, et al. Gender-related differences in clinical management after exercise nuclear testing. J Am Coll Cardiol 1995;26:1457-1464.
14. Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death, differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998;97:535-543.
15. Sharir T, Germano G, Kang X, et al. Prediction of myocardial infarction versus cardiac death by gated myocardial perfusion SPECT: Risk stratification by the amount of stress-induced ischemia and the post-stress ejection fraction. J Nucl Med 2001;42:831-837.
16. Diodati JG, Cannon RO, Epstein SE, Quyyumi AA. Platelet hyperaggregability across the coronary bed in response to rapid atrial pacing in patients with stable coronary artery disease. Circulation 1992;86:1186-1193.
17. Badimon L, Badimon JJ. Mechanism of arterial thrombosis in nonparallel streamlines: Platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 1989;84:1134-1144.
18. Melandri GMD, Semprini FMD, Cervi VBS, et al. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris: A double-blind, randomized, placebo-controlled trial. Circulation 1993;88:2517-2523.
19. Knottenbelt C, Brennan PJ, Meade TW. Antithrombotic treatment and the incidence of angina pectoris. Arch Intern Med 2002;162:881-886.
20. Barron HV, Sciammarella MG, Lenihan K, et al. Effects of the repeated administration of adenosine and heparin on myocardial perfusion in patients with chronic stable angina pectoris. Am J Cardiol 2000;85:1-7.
21. Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003;1 08:420-425.
22. Barbarash OL, Kashtalap VV, Voroncova NL, et al. Effect of thrombolytic therapy on parameters of endothelial function in patients with myocardial infarction. Kardiologiia 2007;47:54-58.
23. Yasunaga C, Nakashima Y, Sueishi K. A role of fibrinolytic activity in angiogenesis: Quantitative assay using in vitro method. Lab Invest 1989;61:698-704.
24. Cheung BMY. A randomised, single centre, double blind, placebo controlled, fixed dose (750 mg, as three capsules, three times daily) study to compare the efficacy and safety of plasmin, an earthworm extract, as a thrombus dissolving agent, with placebo in healthy adult male volunteers over 28 days of treatment. Clinical Trials Centre, Faculty of Medicine, University of Hong Kong, 2002.
25. Zhijie L, Huanmin G, Yaoquan L. Analysis of treatment with plasmin for patients with acute cerebral thrombosis at the early stage. Qingdao Med J 2004;36:1-3.
26. Sun HL, Jiao JD, Pan ZW, et al. The cardioprotective effect and mechanism of lumbrokinase. Yao Xue Xue Bao 2006;41:247-251.
27. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
28. Ji H, Wang L, Bi H, et al. Mechanisms of lumbrokinase in protection of cerebral ischemia. Eur J Pharmacol 2008;590:281-289.